Latest Content

Pretax adjusted income from operations from Express Scripts, Cigna's pharmacy benefit manager, fell by 21.5% compared with the third quarter of 2025, while income from operations of its specialty drug business jumped by 15%.

Annesha White, Pharm.D., M.S., Ph.D., and Fredrick Manasseh, Pharm.D., MBA, BCGP, explain where AI helps managed care pharmacy, where bias creeps in and what skills pharmacists need to oversee it.

Teva’s Weltruza delivers olanzapine monthly under the skin, with no loading doses, oral supplementation or post-injection monitoring required.

Value-based care has scored some cost-saving successes, says Christopher Stanley, M.D., MBA, president of Henry Ford Health's Populance. Health systems that build their own value-based care strategy, rather than adopting particular models one by one, will be in the best position to succeed, he says.

The second half of our conversation with Christopher Stanley, M.D., MBA, the president of Henry Ford Health's Populance and the newest member of the Managed Healthcare Executive editorial advisory board.

The first part of our conversation with Christopher Stanley, M.D., MBA, the president of Henry Ford Health's Populance and the newest member of the Managed Healthcare Executive editorial advisory board.

Unifying care management doubled patient outreach with the same staff, and virtual physical therapy is cutting costs, says Populance's Christopher Stanley, M.D.

Christopher Stanley, M.D., MBA, says Henry Ford Health's growth has led Populance to put its push for outside customers on hold and focus on its own system.

WHO advisers backed adding Oxford/Serum Institute of India and Moderna vaccine candidates to the Tumaini trial against the Bundibugyo Ebola strain.

Geisinger Health Plan expects Medicaid enrollment to fall roughly 10% as H.R. 1 takes effect, President Jeremy Gaskill says, though the timing is still unclear.

As other insurers pull back, Geisinger Health Plan isn’t exiting any Medicare Advantage plans for 2027 and expects to grow, President Jeremy Gaskill says.

The second part of our interview with Jeremy Gaskill, the president of the Geisinger Health Plan. Gaskill discusses trends in the various segments of the health insurance market—Medicaid, Medicare Advantage, the employer-based commercial market and the ACA marketplace.

Democrats won Congress, but with Trump’s veto, their best healthcare tools are funding bills, hearings and bipartisan deals.

In the CONNECT trial, CGM users with type 2 diabetes not on insulin saw larger A1C reductions and more time in range than those using finger-stick testing.

CVS Health announced today that it is reorganizing into two publicly traded companies. The CEO spoke about working on "commercial agreements" between the two. Critics and competitors question how separate they will be.

South Dakota voters rejected Amendment I, which could have ended Medicaid expansion for approximately 31,000 residents if federal funding fell below 90%.

Christine Johnston says Medicaid plans have embraced biosimilars faster than commercial plans and challenges the idea that more expensive means better.

After more than 20 years at Humana, Jeremy Gaskill now leads nonprofit Geisinger Health Plan. The problems are the same, he says, the scale for solving them differs.

Jeremy Gaskill took the reins at the Geisinger Health Plan earlier this year after a long career at Humana. He discusses the similarities and differences between Geisinger and Humana and the advantages of a health plan that is part of a health system.

The retail pharmacies will be in one company and Aetna and CVS Caremark, the PBM, in another, according to news reports.

Swedish registry study links parents’ autoimmune diseases to higher childhood type 1 diabetes risk, suggesting shared genetic susceptibility beyond pregnancy effects.

Christine Johnston warns a thin biosimilar pipeline keeps specialty costs high and slows innovation and urges payers to check their PBM’s top 25 drugs.

Speakers and researchers at this year's meeting in San Diego focused on drug pricing policy, getting savings to patients at the pharmacy counter and keeping people in charge of AI.

The generic twice-yearly HIV prevention shot is expected to cost $40 a year in 120 countries, 16 months after Gilead's original approval.

Annual healthcare costs jump by almost $25,000 with targeted therapy for atopic dermatitis that avoided costs from reduced hospitalizations and ER visits only partly offset, according to recently reported research findings.

Findings from an analysis of IQVIA claims data show a prevalence rate that is five times lower than previous reports. Some of the discrepancy could be chalked up to the difference between using claims data instead of self-reporting by survey respondents.

In the MDT-BRIDGE trial, 92% of patients with stage II-III lung cancer reached surgery or chemoradiation after a midtreatment tumor board review.

Epic Research finds over half of children with type 1 diabetes miss autoantibody testing, risking misdiagnosis and limiting early treatment options like Tzield.

Higher MRI-measured liver disease activity was linked to lower quality of life and more anxiety and activity problems in 802 adults with suspected MASLD/MASH in Europe.

Teen boys with obesity and lower baseline fitness were less likely to see MASLD resolve during a lifestyle program, a Belgian study found.

MassHealth's Katelyn Meyer, Pharm.D., says mandatory coverage, young patients and an unpredictable FDA make planning for new specialty drugs a challenge.